GlassScriptPhysician profile
Hillary A Spears
NPI 1447666912
$2,766.61
in general payments reported to CMS, 2019-2025
31 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $668 · 2023: $552 · 2024: $592 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $481.34 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $292.88 | 2021-2023 | |
| Lilly USA, LLC | $229.60 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $201.40 | 2021-2025 | Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $180.82 | 2021-2024 | Trintellix |
| Pfizer INC. | $168.53 | 2021-2024 | |
| Amgen INC. | $165.74 | 2021-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $157.35 | 2021-2024 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Corium, LLC | $151.23 | 2023-2024 | Azstarys |
| Antares Pharma, INC. | $81.20 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $74.26 | 2022-2023 | Belsomra, Steglatro |
| Axonics, INC. | $66.41 | 2022 | |
| Eisai INC. | $58.83 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $43.45 | 2022-2023 | Austedo |
| Exact Sciences Corporation | $36.40 | 2023-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $33.83 | 2021-2023 | Adzenys Xr-Odt |
| Seqirus USA INC | $33.18 | 2024-2025 | Flucelvax, Fluad |
| Astellas Pharma US INC | $32.72 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.04 | 2024 | Xifaxan |
| Renalytix Ai, INC. | $26.63 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Sanofi Pasteur INC. | $26.42 | 2021-2023 | |
| Abbott Laboratories | $22.80 | 2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $21.17 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.65 | 2025 | Azmiro |
| Supernus Pharmaceuticals, INC. | $20.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.95 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.42 | 2022 | |
| Genentech USA, INC. | $18.58 | 2021 | |
| Merz North America, INC. | $18.29 | 2022 | |
| Tolmar, INC. | $17.15 | 2025 | Jatenzo |
| Currax Pharmaceuticals LLC | $14.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Spears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.